PBM executive: Industry has been discussing end of rebates for a ‘long, long time’
Though the Trump administration’s steps to end drug rebates have been met with outrage from pharmacy benefit managers (PBMs), these companies have been talking about a future without rebates for a long time, experts say.
Byron Mickle, senior vice president for sales and marketing at Navitus Health Solutions, a Wisconsin-based PBM, said during a panel at the World Health Care Congress that eliminating the rebate model is a good foundation for policy to address other issues in drug pricing, such as the cost of specialty drugs.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
Navigating with a trusted partner
Now Available: 9th Annual Drug Trend Report
Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.
Related blogs
Navigating Healthcare and Improving Outcomes
PBM 101: Demystifying the Complex World of Specialty Drugs
Unless you work in the pharmacy benefit management (PBM) industry, it’s easy to assume that a “specialty drug” is simply a more expensive prescription. In reality, specialty medications sit in a separate category, with different rules and far bigger consequences…
